English
简体中文
Total: £ 56.28
Published Date: 2026-03-02 | Pages: 108 | Tables: 106 | Medical Care
The global Investigational New Drug CDMO market was valued at US$ 5306 million in 2025 and is anticipated to reach US$ 8196 million by 2032, at a CAGR of 6.5% from 2026 to 2032.
Investigational New Drug CDMO refers to a Contract Development and Manufacturing Organization (CDMO) that specializes in the development and production of investigational new drugs (INDs). INDs are drugs that are being tested for their safety and efficacy in clinical trials before they receive regulatory approval for general use. An Investigational New Drug CDMO provides services including formulation development, process optimization, scale-up, and manufacturing of INDs to support the drug development process. These organizations play a crucial role in helping pharmaceutical companies bring new drugs from the research phase through to clinical trials.
The North American market for Investigational New Drug CDMO is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for Investigational New Drug CDMO is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The global market for Investigational New Drug CDMO in Pharmaceutical Companies is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 to 2032.
Major global companies of Investigational New Drug CDMO include Catalent, Inc., Lonza, Recipharm AB, Siegfried Holding AG, Patheon Inc., Covance, IQVIA Holdings Inc., Cambrex Corporation, Charles River Laboratories International, Inc., Syneous Health, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global Investigational New Drug CDMO market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Investigational New Drug CDMO. The Investigational New Drug CDMO market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Investigational New Drug CDMO market comprehensively. Regional market sizes by Type, by End User, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Investigational New Drug CDMO manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by End User, and by region.
Market Segmentation
By Company
Catalent, Inc.
Lonza
Recipharm AB
Siegfried Holding AG
Patheon Inc.
Covance
IQVIA Holdings Inc.
Cambrex Corporation
Charles River Laboratories International, Inc.
Syneous Health
Segment by Type
Small Molecule
Large Molecule
Segment by End User
Pharmaceutical Companies
Biotech Companies
Others
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Rest of Asia
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Rest of MEA
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by End User, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Investigational New Drug CDMO companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by End User, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Investigational New Drug CDMO Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Small Molecule
1.2.3 Large Molecule
1.3 Market by End User
1.3.1 Global Investigational New Drug CDMO Market Growth by End User: 2021 vs 2025 vs 2032
1.3.2 Pharmaceutical Companies
1.3.3 Biotech Companies
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Investigational New Drug CDMO Market Perspective (2021–2032)
2.2 Global Investigational New Drug CDMO Growth Trends by Region
2.2.1 Global Investigational New Drug CDMO Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Investigational New Drug CDMO Historic Market Size by Region (2021–2026)
2.2.3 Investigational New Drug CDMO Forecasted Market Size by Region (2027–2032)
2.3 Investigational New Drug CDMO Market Dynamics
2.3.1 Investigational New Drug CDMO Industry Trends
2.3.2 Investigational New Drug CDMO Market Drivers
2.3.3 Investigational New Drug CDMO Market Challenges
2.3.4 Investigational New Drug CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Investigational New Drug CDMO Players by Revenue
3.1.1 Global Top Investigational New Drug CDMO Players by Revenue (2021–2026)
3.1.2 Global Investigational New Drug CDMO Revenue Market Share by Players (2021–2026)
3.2 Global Top Investigational New Drug CDMO Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Investigational New Drug CDMO Revenue
3.4 Global Investigational New Drug CDMO Market Concentration Ratio
3.4.1 Global Investigational New Drug CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Investigational New Drug CDMO Revenue in 2025
3.5 Global Key Players of Investigational New Drug CDMO Head Offices and Areas Served
3.6 Global Key Players of Investigational New Drug CDMO, Products and Applications
3.7 Global Key Players of Investigational New Drug CDMO, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Investigational New Drug CDMO Breakdown Data by Type
4.1 Global Investigational New Drug CDMO Historic Market Size by Type (2021–2026)
4.2 Global Investigational New Drug CDMO Forecasted Market Size by Type (2027–2032)
5 Investigational New Drug CDMO Breakdown Data by End User
5.1 Global Investigational New Drug CDMO Historic Market Size by End User (2021–2026)
5.2 Global Investigational New Drug CDMO Forecasted Market Size by End User (2027–2032)
6 North America
6.1 North America Investigational New Drug CDMO Market Size (2021–2032)
6.2 North America Investigational New Drug CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Investigational New Drug CDMO Market Size by Country (2021–2026)
6.4 North America Investigational New Drug CDMO Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Investigational New Drug CDMO Market Size (2021–2032)
7.2 Europe Investigational New Drug CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Investigational New Drug CDMO Market Size by Country (2021–2026)
7.4 Europe Investigational New Drug CDMO Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Investigational New Drug CDMO Market Size (2021–2032)
8.2 Asia-Pacific Investigational New Drug CDMO Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Investigational New Drug CDMO Market Size by Region (2021–2026)
8.4 Asia-Pacific Investigational New Drug CDMO Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Investigational New Drug CDMO Market Size (2021–2032)
9.2 Latin America Investigational New Drug CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Investigational New Drug CDMO Market Size by Country (2021–2026)
9.4 Latin America Investigational New Drug CDMO Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Investigational New Drug CDMO Market Size (2021–2032)
10.2 Middle East & Africa Investigational New Drug CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Investigational New Drug CDMO Market Size by Country (2021–2026)
10.4 Middle East & Africa Investigational New Drug CDMO Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Catalent, Inc.
11.1.1 Catalent, Inc. Company Details
11.1.2 Catalent, Inc. Business Overview
11.1.3 Catalent, Inc. Investigational New Drug CDMO Introduction
11.1.4 Catalent, Inc. Revenue in Investigational New Drug CDMO Business (2021–2026)
11.1.5 Catalent, Inc. Recent Development
11.2 Lonza
11.2.1 Lonza Company Details
11.2.2 Lonza Business Overview
11.2.3 Lonza Investigational New Drug CDMO Introduction
11.2.4 Lonza Revenue in Investigational New Drug CDMO Business (2021–2026)
11.2.5 Lonza Recent Development
11.3 Recipharm AB
11.3.1 Recipharm AB Company Details
11.3.2 Recipharm AB Business Overview
11.3.3 Recipharm AB Investigational New Drug CDMO Introduction
11.3.4 Recipharm AB Revenue in Investigational New Drug CDMO Business (2021–2026)
11.3.5 Recipharm AB Recent Development
11.4 Siegfried Holding AG
11.4.1 Siegfried Holding AG Company Details
11.4.2 Siegfried Holding AG Business Overview
11.4.3 Siegfried Holding AG Investigational New Drug CDMO Introduction
11.4.4 Siegfried Holding AG Revenue in Investigational New Drug CDMO Business (2021–2026)
11.4.5 Siegfried Holding AG Recent Development
11.5 Patheon Inc.
11.5.1 Patheon Inc. Company Details
11.5.2 Patheon Inc. Business Overview
11.5.3 Patheon Inc. Investigational New Drug CDMO Introduction
11.5.4 Patheon Inc. Revenue in Investigational New Drug CDMO Business (2021–2026)
11.5.5 Patheon Inc. Recent Development
11.6 Covance
11.6.1 Covance Company Details
11.6.2 Covance Business Overview
11.6.3 Covance Investigational New Drug CDMO Introduction
11.6.4 Covance Revenue in Investigational New Drug CDMO Business (2021–2026)
11.6.5 Covance Recent Development
11.7 IQVIA Holdings Inc.
11.7.1 IQVIA Holdings Inc. Company Details
11.7.2 IQVIA Holdings Inc. Business Overview
11.7.3 IQVIA Holdings Inc. Investigational New Drug CDMO Introduction
11.7.4 IQVIA Holdings Inc. Revenue in Investigational New Drug CDMO Business (2021–2026)
11.7.5 IQVIA Holdings Inc. Recent Development
11.8 Cambrex Corporation
11.8.1 Cambrex Corporation Company Details
11.8.2 Cambrex Corporation Business Overview
11.8.3 Cambrex Corporation Investigational New Drug CDMO Introduction
11.8.4 Cambrex Corporation Revenue in Investigational New Drug CDMO Business (2021–2026)
11.8.5 Cambrex Corporation Recent Development
11.9 Charles River Laboratories International, Inc.
11.9.1 Charles River Laboratories International, Inc. Company Details
11.9.2 Charles River Laboratories International, Inc. Business Overview
11.9.3 Charles River Laboratories International, Inc. Investigational New Drug CDMO Introduction
11.9.4 Charles River Laboratories International, Inc. Revenue in Investigational New Drug CDMO Business (2021–2026)
11.9.5 Charles River Laboratories International, Inc. Recent Development
11.10 Syneous Health
11.10.1 Syneous Health Company Details
11.10.2 Syneous Health Business Overview
11.10.3 Syneous Health Investigational New Drug CDMO Introduction
11.10.4 Syneous Health Revenue in Investigational New Drug CDMO Business (2021–2026)
11.10.5 Syneous Health Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Investigational New Drug CDMO Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Key Players of Small Molecule
Table 3. Key Players of Large Molecule
Table 4. Global Investigational New Drug CDMO Market Size Growth by End User (US$ Million): 2021 vs 2025 vs 2032
Table 5. Global Investigational New Drug CDMO Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 6. Global Investigational New Drug CDMO Market Size by Region (US$ Million), 2021–2026
Table 7. Global Investigational New Drug CDMO Market Share by Region (2021–2026)
Table 8. Global Investigational New Drug CDMO Forecasted Market Size by Region (US$ Million), 2027–2032
Table 9. Global Investigational New Drug CDMO Market Share by Region (2027–2032)
Table 10. Investigational New Drug CDMO Market Trends
Table 11. Investigational New Drug CDMO Market Drivers
Table 12. Investigational New Drug CDMO Market Challenges
Table 13. Investigational New Drug CDMO Market Restraints
Table 14. Global Investigational New Drug CDMO Revenue by Players (US$ Million), 2021–2026
Table 15. Global Investigational New Drug CDMO Market Share by Players (2021–2026)
Table 16. Global Top Investigational New Drug CDMO Players by Tier (Tier 1, Tier 2, and Tier 3), based on Investigational New Drug CDMO Revenue, 2025
Table 17. Ranking of Global Top Investigational New Drug CDMO Companies by Revenue (US$ Million) in 2025
Table 18. Global 5 Largest Players Market Share by Investigational New Drug CDMO Revenue (CR5 and HHI), 2021–2026
Table 19. Global Key Players of Investigational New Drug CDMO, Headquarters and Area Served
Table 20. Global Key Players of Investigational New Drug CDMO, Products and Applications
Table 21. Global Key Players of Investigational New Drug CDMO, Date of General Availability (GA)
Table 22. Mergers and Acquisitions, Expansion Plans
Table 23. Global Investigational New Drug CDMO Market Size by Type (US$ Million), 2021–2026
Table 24. Global Investigational New Drug CDMO Revenue Market Share by Type (2021–2026)
Table 25. Global Investigational New Drug CDMO Forecasted Market Size by Type (US$ Million), 2027–2032
Table 26. Global Investigational New Drug CDMO Revenue Market Share by Type (2027–2032)
Table 27. Global Investigational New Drug CDMO Market Size by End User (US$ Million), 2021–2026
Table 28. Global Investigational New Drug CDMO Revenue Market Share by End User (2021–2026)
Table 29. Global Investigational New Drug CDMO Forecasted Market Size by End User (US$ Million), 2027–2032
Table 30. Global Investigational New Drug CDMO Revenue Market Share by End User (2027–2032)
Table 31. North America Investigational New Drug CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 32. North America Investigational New Drug CDMO Market Size by Country (US$ Million), 2021–2026
Table 33. North America Investigational New Drug CDMO Market Size by Country (US$ Million), 2027–2032
Table 34. Europe Investigational New Drug CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 35. Europe Investigational New Drug CDMO Market Size by Country (US$ Million), 2021–2026
Table 36. Europe Investigational New Drug CDMO Market Size by Country (US$ Million), 2027–2032
Table 37. Asia-Pacific Investigational New Drug CDMO Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
Table 38. Asia-Pacific Investigational New Drug CDMO Market Size by Region (US$ Million), 2021–2026
Table 39. Asia-Pacific Investigational New Drug CDMO Market Size by Region (US$ Million), 2027–2032
Table 40. Latin America Investigational New Drug CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 41. Latin America Investigational New Drug CDMO Market Size by Country (US$ Million), 2021–2026
Table 42. Latin America Investigational New Drug CDMO Market Size by Country (US$ Million), 2027–2032
Table 43. Middle East & Africa Investigational New Drug CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 44. Middle East & Africa Investigational New Drug CDMO Market Size by Country (US$ Million), 2021–2026
Table 45. Middle East & Africa Investigational New Drug CDMO Market Size by Country (US$ Million), 2027–2032
Table 46. Catalent, Inc. Company Details
Table 47. Catalent, Inc. Business Overview
Table 48. Catalent, Inc. Investigational New Drug CDMO Product
Table 49. Catalent, Inc. Revenue in Investigational New Drug CDMO Business (US$ Million), 2021–2026
Table 50. Catalent, Inc. Recent Development
Table 51. Lonza Company Details
Table 52. Lonza Business Overview
Table 53. Lonza Investigational New Drug CDMO Product
Table 54. Lonza Revenue in Investigational New Drug CDMO Business (US$ Million), 2021–2026
Table 55. Lonza Recent Development
Table 56. Recipharm AB Company Details
Table 57. Recipharm AB Business Overview
Table 58. Recipharm AB Investigational New Drug CDMO Product
Table 59. Recipharm AB Revenue in Investigational New Drug CDMO Business (US$ Million), 2021–2026
Table 60. Recipharm AB Recent Development
Table 61. Siegfried Holding AG Company Details
Table 62. Siegfried Holding AG Business Overview
Table 63. Siegfried Holding AG Investigational New Drug CDMO Product
Table 64. Siegfried Holding AG Revenue in Investigational New Drug CDMO Business (US$ Million), 2021–2026
Table 65. Siegfried Holding AG Recent Development
Table 66. Patheon Inc. Company Details
Table 67. Patheon Inc. Business Overview
Table 68. Patheon Inc. Investigational New Drug CDMO Product
Table 69. Patheon Inc. Revenue in Investigational New Drug CDMO Business (US$ Million), 2021–2026
Table 70. Patheon Inc. Recent Development
Table 71. Covance Company Details
Table 72. Covance Business Overview
Table 73. Covance Investigational New Drug CDMO Product
Table 74. Covance Revenue in Investigational New Drug CDMO Business (US$ Million), 2021–2026
Table 75. Covance Recent Development
Table 76. IQVIA Holdings Inc. Company Details
Table 77. IQVIA Holdings Inc. Business Overview
Table 78. IQVIA Holdings Inc. Investigational New Drug CDMO Product
Table 79. IQVIA Holdings Inc. Revenue in Investigational New Drug CDMO Business (US$ Million), 2021–2026
Table 80. IQVIA Holdings Inc. Recent Development
Table 81. Cambrex Corporation Company Details
Table 82. Cambrex Corporation Business Overview
Table 83. Cambrex Corporation Investigational New Drug CDMO Product
Table 84. Cambrex Corporation Revenue in Investigational New Drug CDMO Business (US$ Million), 2021–2026
Table 85. Cambrex Corporation Recent Development
Table 86. Charles River Laboratories International, Inc. Company Details
Table 87. Charles River Laboratories International, Inc. Business Overview
Table 88. Charles River Laboratories International, Inc. Investigational New Drug CDMO Product
Table 89. Charles River Laboratories International, Inc. Revenue in Investigational New Drug CDMO Business (US$ Million), 2021–2026
Table 90. Charles River Laboratories International, Inc. Recent Development
Table 91. Syneous Health Company Details
Table 92. Syneous Health Business Overview
Table 93. Syneous Health Investigational New Drug CDMO Product
Table 94. Syneous Health Revenue in Investigational New Drug CDMO Business (US$ Million), 2021–2026
Table 95. Syneous Health Recent Development
Table 96. Research Programs/Design for This Report
Table 97. Key Data Information from Secondary Sources
Table 98. Key Data Information from Primary Sources
Table 99. Authors List of This Report
List of Figures
Figure 1. Investigational New Drug CDMO Picture
Figure 2. Global Investigational New Drug CDMO Market Size Comparison by Type (US$ Million), 2021–2032
Figure 3. Global Investigational New Drug CDMO Market Share by Type: 2025 vs 2032
Figure 4. Small Molecule Features
Figure 5. Large Molecule Features
Figure 6. Global Investigational New Drug CDMO Market Size by End User (US$ Million), 2021–2032
Figure 7. Global Investigational New Drug CDMO Market Share by End User: 2025 vs 2032
Figure 8. Pharmaceutical Companies Case Studies
Figure 9. Biotech Companies Case Studies
Figure 10. Others Case Studies
Figure 11. Investigational New Drug CDMO Report Years Considered
Figure 12. Global Investigational New Drug CDMO Market Size (US$ Million), Year-over-Year: 2021–2032
Figure 13. Global Investigational New Drug CDMO Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 14. Global Investigational New Drug CDMO Market Share by Region: 2025 vs 2032
Figure 15. Global Investigational New Drug CDMO Market Share by Players in 2025
Figure 16. Global Investigational New Drug CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 17. The Top 10 and 5 Players Market Share by Investigational New Drug CDMO Revenue in 2025
Figure 18. North America Investigational New Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 19. North America Investigational New Drug CDMO Market Share by Country (2021–2032)
Figure 20. United States Investigational New Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 21. Canada Investigational New Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 22. Europe Investigational New Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 23. Europe Investigational New Drug CDMO Market Share by Country (2021–2032)
Figure 24. Germany Investigational New Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 25. France Investigational New Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 26. U.K. Investigational New Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 27. Italy Investigational New Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 28. Russia Investigational New Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 29. Ireland Investigational New Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 30. Asia-Pacific Investigational New Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 31. Asia-Pacific Investigational New Drug CDMO Market Share by Region (2021–2032)
Figure 32. China Investigational New Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 33. Japan Investigational New Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 34. South Korea Investigational New Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 35. Southeast Asia Investigational New Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 36. India Investigational New Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 37. Australia & New Zealand Investigational New Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 38. Latin America Investigational New Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 39. Latin America Investigational New Drug CDMO Market Share by Country (2021–2032)
Figure 40. Mexico Investigational New Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 41. Brazil Investigational New Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 42. Middle East & Africa Investigational New Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 43. Middle East & Africa Investigational New Drug CDMO Market Share by Country (2021–2032)
Figure 44. Israel Investigational New Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 45. Saudi Arabia Investigational New Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 46. UAE Investigational New Drug CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 47. Catalent, Inc. Revenue Growth Rate in Investigational New Drug CDMO Business (2021–2026)
Figure 48. Lonza Revenue Growth Rate in Investigational New Drug CDMO Business (2021–2026)
Figure 49. Recipharm AB Revenue Growth Rate in Investigational New Drug CDMO Business (2021–2026)
Figure 50. Siegfried Holding AG Revenue Growth Rate in Investigational New Drug CDMO Business (2021–2026)
Figure 51. Patheon Inc. Revenue Growth Rate in Investigational New Drug CDMO Business (2021–2026)
Figure 52. Covance Revenue Growth Rate in Investigational New Drug CDMO Business (2021–2026)
Figure 53. IQVIA Holdings Inc. Revenue Growth Rate in Investigational New Drug CDMO Business (2021–2026)
Figure 54. Cambrex Corporation Revenue Growth Rate in Investigational New Drug CDMO Business (2021–2026)
Figure 55. Charles River Laboratories International, Inc. Revenue Growth Rate in Investigational New Drug CDMO Business (2021–2026)
Figure 56. Syneous Health Revenue Growth Rate in Investigational New Drug CDMO Business (2021–2026)
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed
